drugset / Trial / NCT00834067
Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
Timeline
- Start
- 2003-10
- Primary completion
- 2003-11
- Completion
- 2003-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 25 mg | — |
| Subject | Moexipril | Small molecule | 15 mg | — |
Indications
No indication recorded.